Novanta, a technology provider to medical and industrial OEMs, has agreed to acquire Riverpoint Medical, a developer and manufacturer of minimally invasive surgical consumables, from Arlington Capital Partners.
The transaction includes $1.2 billion in upfront cash consideration and a potential $250 million milestone payment in the first quarter of 2027, with closing expected in the third quarter of 2026, subject to regulatory approvals and customary conditions. The acquisition supports Novanta’s (Nasdaq: NOVT) strategy of increasing recurring revenue streams, expanding its medical OEM partnerships and accelerating long-term revenue and cash flow growth. Riverpoint Medical develops, designs, and manufactures medical devices focused on advanced surgical fibers and related technologies. The company supplies private-label minimally invasive surgical consumables and instruments to medical OEMs serving high-growth markets including sports medicine, trauma, and cardiovascular surgery.
Baird and JPMorgan Securities advised Novanta financially, while Ropes & Gray and King & Spalding served as legal counsel. Jefferies acted as sole financial advisor to Riverpoint Medical, and Goodwin Procter served as its legal advisor.